Clinically validated approaches to the treatment of autoimmune diseases

Bibliography

• Report of the Autoimmune Diseases Coordinating Committee, National Institutes of Health. October 2000. Available from: http://www3.niaid.nih.gov/topics/autoimmune/PDF/adccrev.pdf [Last accessed 19 December 2009]
   Google Scholar
• Progress in Autoimmune Disease Research, Report to Congress. The Autoimmune Diseases Coordinating Committee, National Institutes of Health. March 2005. Available from: http://www3.niaid.nih.gov/topics/autoimmune/PDF/ADCCFinal.pdf [Last accessed 19 December 2009]
   Google Scholar
• Jacobsen DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immun Immunopathol 1997;84:223-43
   PubMedGoogle Scholar
• Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121(10 Suppl 1):S21-31
   Web of Science ®Google Scholar
• Hyrich KL. Patients with suspected rheumatoid arthritis should be referred early to rheumatology. BMJ 2008;336:215-16
   PubMed Web of Science ®Google Scholar
• Felson DT. Whither the ACR20? J Rheumatol 2004;31:835-7
   PubMed Web of Science ®Google Scholar
• Felson DT, Furst DE, Boers M. Rationale and strategies for reevaluating the ACR20. J Rheumatol 2007;34:1184-7
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75
   PubMed Web of Science ®Google Scholar
• Choy EH, Hazleman B, Smith M, Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxf) 2002;41:1133-7
   PubMed Web of Science ®Google Scholar
• Pappas DA, Bathan JM, Hanicq D, Golimumab. Nat Rev Drug Discov 2009;8:695-6
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen S, Moreland L, Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-19
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96
   Google Scholar
• Stoll JG, Yasothan U. Rheumatoid arthritis market. Nat Rev Drug Discov 2009;8:693-4
   PubMed Web of Science ®Google Scholar
• Cohen SB, Dore RK, Lane NE, Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis. Arthritis Rheum 2008;58:1299-309
   PubMed Web of Science ®Google Scholar
• Dore RK, Cohen SB, Lane NE, Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2009. [Epub ahead of print]; PubMed PMID:19734132; doi 10.1136/ard.2009.112920
   Web of Science ®Google Scholar
• Ostör AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin Rheumatol 2008;27:1343-53
   PubMed Web of Science ®Google Scholar
• Rokosz LL, Beasley JR, Carroll CD, Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12:883-903
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng TT, Chindalore V, Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44
   PubMed Web of Science ®Google Scholar
• Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18
   PubMed Web of Science ®Google Scholar
• Coombs JH, Bloom BJ, Breedveld FC, Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus Kinase (JAK) inhibitor: results from a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2009. [Epub 8 July 2009]; PMID 19587388, doi 10.1136/ard.2009.108159
   Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase Iia trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905
   PubMed Web of Science ®Google Scholar
• Gladman DD. Targeted therapies for psoriatic arthritis. Nat Rev Rheumatol 2009;5:241-2
   PubMed Web of Science ®Google Scholar
• Traub M, Marshall K. Psoriasis – pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 2007;12:319-30
   PubMed Web of Science ®Google Scholar
• Jacobsen CC, Kimball AB. Rethinking the psoriasis and severity index: the impact of area should be increased. Br J Dermatol 2004;151:381-7
   PubMed Web of Science ®Google Scholar
• Boker A, Kimball AB, Rolz-Cruz G. Biologicals in the treatment of psoriasis. Curr Opin Investig Drugs 2007;8:939-46
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Qin J-Z, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allerg Immunol 2007;3:45-56
   Google Scholar
• Papp K, Bissonnette R, Rosoph L, Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-42
   PubMed Web of Science ®Google Scholar
• Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis – a multifaceted adversary. Nat Rev Drug Discov 2008;7:909-25
   PubMed Web of Science ®Google Scholar
• Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J Neurol 2005;252:(Suppl 5):v46-53
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Biodrugs 2002;16:183-200
   PubMed Web of Science ®Google Scholar
• De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58:417-32
   PubMed Web of Science ®Google Scholar
• Segal BS, Constantinescu CS, Raychaudhuri A, Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804
   PubMed Web of Science ®Google Scholar
• Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008;255:(Suppl 1):26-36
   PubMed Web of Science ®Google Scholar
• Gribben JG, Hallek M. Rediscovering alemtuzuman: current and emerging therapeutic roles. Br J Haematol 2009;144;818-31
   PubMed Web of Science ®Google Scholar
• Hirst CL, Pace A, Pickersgill TP, Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255:231-8
   PubMed Web of Science ®Google Scholar
• DeAngelis T, Lublin F. Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr Opin Neurol 2008;21:261-71
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
   PubMed Web of Science ®Google Scholar
• Rose JW, Burns JB, Bjorklund J, Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-9
   PubMed Web of Science ®Google Scholar
• Gasperini C, Cefaro LA, Borriello G, Emerging oral drugs for multiple sclerosis. Exp Opin Emerg Drugs 2008;13:465-77
   PubMed Web of Science ®Google Scholar
• O'Connor P, Comi G, Montalban X, Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A. Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008;24:440-7
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81
   PubMed Web of Science ®Google Scholar
• Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 2008;336:1062-6
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Lewis JD, Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol 2008;103:3123-31
   Google Scholar
• Sands BE, Anderson FH, Bernstein CN, Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9
   PubMed Web of Science ®Google Scholar
• Rahman T, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39
   PubMed Web of Science ®Google Scholar
• Harley JB, Alarcón-Riquelme ME, Criswell LA, ; International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN); Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12
   PubMed Web of Science ®Google Scholar
• Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmunity 2009;32;223-30
   PubMed Web of Science ®Google Scholar
• Monneaux F, Muller S. Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther 2009;11:234
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80
   PubMed Web of Science ®Google Scholar
• Merrill JT, Buyon JP. Connective tissue diseases: what does the death of Riquent hold for the future of SLE? Nat Rev Rheumatol 2009;5:306-7
   PubMed Web of Science ®Google Scholar
• Coca A, Sanz I. B cell depletion in lupus and Sjögren's syndrome: an update. Curr Opin Rheumatol 2009;21:483-8
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Díaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu, et al. Arthritis Rheum 2009;61:1281-2
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
   PubMed Web of Science ®Google Scholar
• Niewold TB, Hua J, Lehman TJ, High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8:492-502
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15
   PubMed Web of Science ®Google Scholar
• Niewold TB. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol 2008;14:131-2
   PubMed Web of Science ®Google Scholar
• Yao Y, Richman L, Higgs BW, Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96
   PubMed Web of Science ®Google Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Maddison PJ, Bulpitt KJ, CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum 1995:38:1589-94
   PubMed Web of Science ®Google Scholar
• Wendling D, Racadot E, Wijdenes J, A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1998;25:1457-61
   PubMed Web of Science ®Google Scholar
• Moreland LW, Pratt PW, Mayes MD, Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995;38:1581-8
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Barkhof F, Truyen L, Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4
   PubMed Web of Science ®Google Scholar
• Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65
   PubMed Web of Science ®Google Scholar
• Hamon MA, Nicolas G, Deviere F, Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. Rev Neurol (Paris) 2007;163:1232-5
   PubMed Web of Science ®Google Scholar
• Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700
   PubMed Web of Science ®Google Scholar
• Glabinski AR, Bielecki B, Kawczak JA, Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity 2004;37:465-71
   PubMed Web of Science ®Google Scholar
• Taoufik E, Tseveleki V, Euagelidou M, Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. Neurodegener Dis 2008;5:32-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
   PubMed Web of Science ®Google Scholar
• Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34:(Suppl 1):7-11
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009;131:308-16
   PubMed Web of Science ®Google Scholar
• Fries W, Muja C, Crisafulli C, Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int J Med Sci 2008;5:169-80
   PubMedGoogle Scholar
• Suntharalingam G, Perry MR, Ward S, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28
   PubMed Web of Science ®Google Scholar
• Schraven B, Kalinke U. CD28 Superagonists: what makes the difference in humans? Immunity 2008;28:591-5
   PubMed Web of Science ®Google Scholar
• St Clair EW. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 2008;118:1344-47
   PubMed Web of Science ®Google Scholar
• Schneider CK, Kalinke U, Löwer J. TGN1412 – a regulator's perspective. Nat Biotechnol 2006;24:493-6
   PubMed Web of Science ®Google Scholar
• Muller PY, Brennan FR. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009;85:247-58
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796-804
   PubMed Web of Science ®Google Scholar
• Garber K. Immunology's quiet upheaval. Nat Biotech 2009;27:687-9
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. Erratum in: JAMA 2006;295:2482
   PubMed Web of Science ®Google Scholar
• Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rhemuatology 2005;44:714-20
   PubMed Web of Science ®Google Scholar
• Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-52
   Google Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2009;68:25-32
   Google Scholar
• Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-28
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33
   PubMed Web of Science ®Google Scholar
• Boren EJ, Cheema GS, Naguwa SM, The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-8
   PubMed Web of Science ®Google Scholar
• Molloy ES, Cabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 2008;8:144-6
   Google Scholar
• Setoguchi S, Solomon DH, Weinblatt ME, Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64
   PubMed Web of Science ®Google Scholar
• Hauser SL. Multiple lessons for multiple sclerosis. N Engl J Med 2008;359:1838-41
   PubMed Web of Science ®Google Scholar
• De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58:417-32
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL, IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Demyelination occurring during anti-TNF-a therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9
   PubMed Web of Science ®Google Scholar
• Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65
   PubMed Web of Science ®Google Scholar
• Van Oosten BW, Barkhof F, Truyen L, Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4
   PubMed Web of Science ®Google Scholar
• Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008;7:411-19
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9
   PubMed Web of Science ®Google Scholar
• Watier H. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin Biol Ther 2005;5:(Suppl 1):S29-36
   PubMed Web of Science ®Google Scholar
• Danila MI, Hughes LB, Bridges SL. Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics 2008;9:1011-15
   PubMed Web of Science ®Google Scholar
• Rokosz LL, Beasley JR, Carroll CD, Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12:883-903
   PubMed Web of Science ®Google Scholar
• McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol (Oxf) 2008;69:687-96
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
   PubMed Web of Science ®Google Scholar
• Cohen SB, Moreland LW, Cush JJ. A multicentre, double blind, randomised, placebo controlled trial of anakinra(Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-8
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23, Erratum in: N Engl J Med. 2005;353:2311
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66
   PubMed Web of Science ®Google Scholar
• Flytström I, Stenberg B, Svensson A, Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008;158:116-21
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK, Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-80, Erratum in: JAMA 2004;291:1070
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Jacobsm LD, Cookfair DL, Rudick RA, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS study group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504, See also: Li DKB, Paty DW, et al. Magnetic resonance imaging results of the PRISMS Trial: a randomized, double-blind, placebo-controlled study of interferon-b1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76, See also: Martinelli BF, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-55
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Harvdova E, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, ; CAMMS223 Trial Investigators, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
   PubMed Web of Science ®Google Scholar
• Feagan BG, Greenberg GR, Wild G, Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
   Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, ; for the Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008;135:1130-41
   PubMed Web of Science ®Google Scholar